Scheduled Autologous PRP Guided Injection in the Maxillary Bony Defects

Horus University

Status and phase: Completed; Phase 2

Conditions: Bony Defect

Treatments: Biological: Autologous platelet-rich plasma

Study type: Interventional

Funder types: Other

Identifiers

NCT07108933

PRP in maxillary bone defects

Details and patient eligibility

About

Scheduled autologous platelet-rich plasma guided injection is done in critical-sized maxillary bony defects after surgical excision of non- malignant lesions.

Full description

The study aims to detect the effect of scheduled autologous platelet-rich plasma- guided injection in the healing process of critical-sized maxillary bony defects after surgical removal of non-malignant lesions by using bone volumetric analysis and density measuring with cone beam computed tomography.

Enrollment: 16 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age: 18-65 years (adults within a specific age range).

Diagnosis: Non-malignant maxillary bony defects (e.g., benign tumors or cysts).

Health: Generally healthy participants who can tolerate surgery.

Platelet Function: No platelet disorders or blood-related conditions.

Willingness: Informed consent and ability to follow the protocol.

No Use of Blood Thinners: No current use of anticoagulants like aspirin.

Exclusion criteria

• Age: Children (under 18) and elderly (over 75).

Malignant Lesions: Participants with cancer or pre-cancerous conditions.

Systemic Illness: Severe conditions (e.g., uncontrolled diabetes, autoimmune disorders).

Platelet Disorders: Low platelet count or bleeding disorders (e.g., hemophilia).

Infections: Active infections or inflammatory conditions (e.g., periodontal disease).

Pregnancy: Women who are pregnant or breastfeeding.

Recent Surgery/Trauma: Recent maxillary surgery or trauma.

Uncontrolled Medications: Use of blood thinners, NSAIDs, or immunosuppressive drugs.

Non-compliance: Unwillingness or inability to follow-up with the protocol.

Substance Abuse: Active drug or alcohol abuse.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

16 participants in 1 patient group

Injection

Other group

Description:

Scheduled injection of autologous platelet-rich plasma

Treatment:

Biological: Autologous platelet-rich plasma